口服米非司酮配伍米索前列醇与阴道内放置米索前列醇终止12～22周妊娠的比较性研究

为比较口服米非司酮配伍米索前列醇与单独阴道内置米索前列醇终止12～22周妊娠的临床安全性及有效性。将65例要求终止妊娠的孕妇随机分为二组:组Ⅰ(32例)口服米非司酮配伍米索前列醇;组Ⅱ(33例)于阴道内放置米索前列醇。结果显示:两组间引产成功率比较无显著差异(组Ⅰ96.88％,组Ⅱ96.97％,P>0.05)。用米索至分娩时间及腹痛至分娩时间组Ⅰ均显著短于组Ⅱ(P<0.01)。表明两种终止妊娠方法在临床应用均安全、有效。口服米非司酮配伍米索前列醇患者腹痛时间短,但服药时间较长,阴道单独用米索方案更为简便,价廉,在第三世界国家及贫困地区应用更具优越性。

A Comparetive Study between Mifepristone Combined with Misoprostol Orally and Misoprostol Intrav-aginally for Termination of 12 - 22 Week Pregnancy.

Objective:To compare the clinical safety and efficiency. Method: 65 pregnant women (12 - 22 week) were randomlly allocated into two groups: Group 1(32 cases) was administrated with Mifepristone combined with Misoprostol orally; Group 2(33 cases) was given Misoprostol intravaginally. Result: There is no significant difference in success rate of labor induction and side effects of medicine between group 1 and 2(P>0. 05). The time from the administration of Misoprostol to labor and from abdominal pain to labor in group 1 was shorter than that in group 2(P<0.01). Conclusion; Both methods of labor induction are safe and effective, Mifepristone combined with Misoprostol orally has short abdominal pain time, but need more time for labor induction. Comparatively, Misoprostol administrated intravaginally is more ecnomic, simpler, and more suitable to the developing country and indigent region.